AtriCure (NASDAQ:ATRC) Insider Sells $233,280.00 in Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Vinayak Doraiswamy sold 6,000 shares of AtriCure stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $38.88, for a total value of $233,280.00. Following the completion of the transaction, the insider owned 86,511 shares in the company, valued at approximately $3,363,547.68. This represents a 6.49% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

AtriCure Price Performance

Shares of NASDAQ:ATRC opened at $37.76 on Friday. The company has a market cap of $1.92 billion, a price-to-earnings ratio of 179.82 and a beta of 1.24. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.18. The firm has a 50 day simple moving average of $31.10 and a 200 day simple moving average of $31.34. AtriCure, Inc. has a one year low of $25.36 and a one year high of $43.18.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. The firm had revenue of $153.60 million for the quarter, compared to analysts’ expectations of $151.80 million. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Research analysts predict that AtriCure, Inc. will post 0.2 earnings per share for the current fiscal year.

Key Stories Impacting AtriCure

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure’s recent second-quarter results exceeded expectations, with earnings per share of $0.18 versus the $0.13 analyst estimate and revenue of $153.6 million versus $151.8 million expected. The company also improved from a year-ago loss, supporting its growth and profitability outlook. AtriCure second-quarter results presentation
• Positive Sentiment: UBS lowered its price target from $55 to $50 but retained a Buy rating. The revised target still indicates meaningful potential upside and suggests the analyst remains constructive on AtriCure’s medical-device business. UBS AtriCure price target report
• Neutral Sentiment: Options-market coverage points to the possibility of a significant upcoming move in ATRC, but the available information does not establish whether traders are positioning for a rise or decline. Elevated options activity could contribute to short-term volatility. AtriCure options activity article
• Neutral Sentiment: New share-registration filings may give AtriCure additional financing flexibility. However, investors may monitor the filings for potential future share issuance and dilution. AtriCure share registration article
• Negative Sentiment: Insiders sold approximately $1.42 million of AtriCure shares. Director Sven Wehrwein reduced his position by about 38%, while insiders Justin J. Noznesky and Vinayak Doraiswamy each sold roughly 6% of their holdings. The clustered selling may weigh on sentiment, particularly after ATRC’s strong advance toward its 52-week high. AtriCure insider selling report

Institutional Investors Weigh In On AtriCure

Institutional investors have recently modified their holdings of the company. Geneos Wealth Management Inc. acquired a new stake in shares of AtriCure during the second quarter worth $37,000. Harbor Investment Advisory LLC acquired a new position in AtriCure in the second quarter valued at $40,000. Smartleaf Asset Management LLC boosted its position in AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the last quarter. Fifth Third Bancorp bought a new stake in AtriCure during the first quarter valued at $51,000. Finally, Global Retirement Partners LLC acquired a new stake in AtriCure during the 4th quarter worth about $73,000. 99.11% of the stock is owned by institutional investors.

Analyst Ratings Changes

ATRC has been the subject of several recent research reports. Wall Street Zen downgraded AtriCure from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings raised shares of AtriCure from a “sell (e+)” rating to a “sell (d+)” rating in a report on Tuesday. Citigroup reaffirmed a “market outperform” rating on shares of AtriCure in a research note on Tuesday, July 21st. Zacks Research raised shares of AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Friday, July 24th. Finally, Canaccord Genuity Group increased their price target on AtriCure from $53.00 to $55.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, AtriCure presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.50.

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.